Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
With a slashed valuation the newly listed biotech heads for phase 3.
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
An actinium-based backup and Werner helicase inhibitor are notable absences.
But the Astra/Daiichi ADC stumbles in lung cancer.
